Infliximab Reduces Colectomy in Patients with Moderate-to-Severe Ulcerative Colitis: Analysis from ACT 1 and ACT 2
William J. Sandborn(University of San Diego), J F Colombel(Icahn School of Medicine at Mount Sinai), A. Olson, Brian G. Feagan(Western University), Daniel Rachmilewitz(Hadassah Academic College), Jing Lü(Inner Mongolia Agricultural University), P. Rutgeerts, Gary Lichtenstein(University of Pennsylvania), S. B. Hanauer(University of Chicago), Walter Reinisch(Medical University of Vienna), W de Villiers(University of Cape Town), Daniel H. Present(Communities In Schools of Orange County), Jewel Johanns(Johnson & Johnson (United States)), Bruce E. Sands(Icahn School of Medicine at Mount Sinai)
Cited by 2
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k